Advanced Solid Tumors Cancer
Conditions
Keywords
Cancer, Advanced Solid Tumor, Neoplasm
Brief summary
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
Interventions
DRUGOsimertinib
It is administered orally everyday.
DRUGNivolumab
It is an intravenous infusion administered every 14 days.
It is administered by infusion in 21-day dosing cycles.
DRUGErlotinib
It is administered orally everyday.
Sponsors
AbbVie
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participant must have advanced Non-Small Cell Lung Cancer (NSCLC) that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit. * Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. For Monotherapy Expansion Cohort, participant must have ECOG Performance Status of 0 or 1. * Participant must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. * Participant has archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue confirmed available for analyses. * Participant has adequate bone marrow, renal, and hepatic function. * Women of childbearing potential must have a negative serum pregnancy test at baseline. * Participants in the combination therapy arms A and D must be eligible to receive erlotinib, or nivolumab per most locally approved labeling, or at the discretion of the Investigator. * Participants in the combination therapy Arm E must satisfy following criteria. * Participant must have metastatic/locally advanced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resistant to osimertinib. * Participant must have received at least 1 but no more than 2 prior regimens, one of which must have contained osimertinib. Participant must have had disease progression while on osimertinib. Only 1 prior regimen may have contained chemotherapy. Consecutive EGFR TKIs will count as 1 regimen * Participant must have available post-progression tumor tissue for central c-Met immunohistochemistry (IHC) testing. * Participant has adequate bone marrow function. * Participants in the Monotherapy Expansion Cohort must satisfy following criteria. * Participant must have locally advanced or metastatic, non-squamous, EGFR wild type, c-Met+ NSCLC. Participants must not have adenosquamous histology. * Participant must have received no more than 2 lines of prior systemic therapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the locally advanced or metastatic setting. * Participant must have progressed on systemic cytotoxic chemotherapy (or are ineligible for systemic cytotoxic chemotherapy) and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible for an immune checkpoint inhibitor), and prior anti-cancer therapies targeting driver gene alterations (if applicable). * Participant should not have received prior c-Met-targeted antibody-based therapies.
Exclusion criteria
* Participant has received radiation therapy to the lung \< 6 months prior to the first dose of ABBV-399. * Participant has received anticancer therapy including chemotherapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days or herbal therapy within 7 days prior to the first dose of ABBV-399. * Participant has uncontrolled metastases to the central nervous system (CNS) based on head CT or MRI. Participants with brain metastases may be eligible 2-4 weeks after definitive therapy to all known sites of CNS disease provided they are asymptomatic and either off or on a non-increasing dose (in last 2 weeks) of systemic steroids and not on anticonvulsants for seizure activity directly related to progressive CNS metastases. * Participant has history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids. * Participant has evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or interstitial lung disease (ILD) within 3 months of the planned first dose of the study drug. * Participant has unresolved clinically significant adverse events \>= Grade 2 from prior anticancer therapy, except for alopecia or anemia. * Participant has had major surgery within 21 days prior to the first dose of ABBV-399. * Participant has a clinically significant condition(s) described in the protocol. * History of major immunologic reaction to any Immunoglobulin G (IgG) containing agent. * Participant has any medical condition which in the opinion of the Investigator or Medical Monitor places the participant at an unacceptably high risk for toxicities. * Participant is a lactating or pregnant female. * Participant with known active COVID-19 infection, subjects with signs/symptoms associated with COVID-19 infection or known exposure to a confirmed case of COVID-19 infection during 14 days prior to Screening must be screen failed and may only rescreen after they have recovered from COVID-19 and they are no longer considered contagious, per investigator assessment. * Participants enrolled on the combination therapy phase must satisfy the above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events | Up to 24 Months | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
| Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or Nivolumab | Up to 24 Months | The RPTD of ABBV-399 when administered as monotherapy and in combination with osimertinib, erlotinib or nivolumab will be determined during the dose escalation phase of the study. RPTD will be determined using available safety and pharmacokinetics data. |
| Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t) | Up to 24 months | AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration. |
| Maximum observed plasma concentration (Cmax) | Up to 24 months | Maximum observed plasma concentration (Cmax). |
| Time to Cmax (Tmax) | Up to 24 months | Time to Cmax (Tmax). |
| Terminal elimination half life | Up to 24 months | Terminal elimination half life. |
Countries
Belgium, Finland, France, Italy, Japan, Netherlands, South Korea, Taiwan, United States
Outcome results
None listed